Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2009-017798-39-IT
EUCTR2009-017798-39-IT
Active, not recruiting
Not Applicable

An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study) - ND

ISTITUTO NAZIONALE PER LA CURA TUMORI0 sitesJune 15, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsProstate cancer, biochemical failure after all potentially curative standard local therapies (radiotherapy, brachytherapy and surgery) or biochemical progression while patients have castrated levels of testosterone or after first-line anti hormonal therapyMedDRA version: 12.1Level: LLTClassification code 10001200Term: Adenocarcinoma of the prostate stage I

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostate cancer, biochemical failure after all potentially curative standard local therapies (radiotherapy, brachytherapy and surgery) or biochemical progression while patients have castrated levels of testosterone or after first-line anti hormonal therapy
Sponsor
ISTITUTO NAZIONALE PER LA CURA TUMORI
Status
Active, not recruiting
Last Updated
12 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 15, 2010
End Date
TBD
Last Updated
12 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Male

Investigators

Sponsor
ISTITUTO NAZIONALE PER LA CURA TUMORI

Eligibility Criteria

Inclusion Criteria

  • •1\.Aged 18 years or older
  • •2\.Histological or cytological confirmation of prostate adenocarcinoma
  • •3\.Biochemical recurrence after potentially curative standard therapies for localized disease or Biochemical progression while the patient has castrate levels of testosterone (Castration resistant prostate cancer) or patients with progression after first\-line anti hormonal treatment
  • •4\. Negative bone scan (performed no more than 90 days prior enrollment)
  • •5\.HLA A1, A2, A3, A24 or B7 as assessed by HLA Genotyping
  • •6\.ECOG Performance status 0 or 1
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range

Exclusion Criteria

  • •1\.Active malignancy other than prostate cancer
  • •2\.Clinical evidence of metastatic disease, local recurrence of pelvic lymph node disease
  • •3\.PSA \> 10 ng/ml
  • •4\.History of past or current autoimmune disease or primary or secondary immunodeficiencies
  • •5\.Known hypersensitivity to any component of trial treatment

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma.nresectable and progressive metastatic cutaneous melanomaMedDRA version: 9.1Level: LLTClassification code 10027480Term: Metastatic malignant melanoma
EUCTR2004-001937-40-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER68
Active, not recruiting
Phase 1
Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanomanresectable and progressive metastatic cutaneous melanomaMedDRA version: 7.0Level: LLTClassification code 10027155
EUCTR2004-001937-40-ESEuropean Organisation for Research and Treatment of Cancer
Active, not recruiting
Not Applicable
Safety and reactogenicity of GSK Biologicals’ DTPa-IPV/Hib (Infanrix-IPV/Hib) in infants.Healthy volunteers (Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b diseases).Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2015-001513-27-Outside-EU/EEAGlaxoSmithKline Biologicals50
Active, not recruiting
Phase 1
Aditec Flu 2 Study: Understanding the genetic basis for immune responses to flu vaccines in children and adultsThis trial is investigating healthy children and adult's gene expression and immune response to the Fluad (MF59)-adjuvanted trivalent influenza vaccine and also comparing these to the local and general reactions following vaccine administration. Healthy children will be immunised with 2 doses, adult with 1 dose.Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2015-001648-12-GBniversity of Oxford120
Active, not recruiting
Phase 1
A Study of Safety and Clinical Activity of Cancer Immunotherapy Plus Chemotherapy in Metastatic Melanoma PatientsPatients with unresectable and progressive metastatic cutaneous melanoma, whose tumor expresses MAGE-A3.MedDRA version: 16.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2008-001918-25-BEGlaxoSmithKline Biologicals40